Background:　With　the　growing　rate　of　obesity　and　associated　chronic　conditions　in　China,　there　is　a　need　to　assess　the　health　and　economic　burdens　of　obesity　and　examine　the　effectiveness　of　pharmaceutical,　medical,　and　comprehensive　weight-loss　interventions.　Areas　covered:　This　article　reviewed　publications　retrieved　from　PubMed　and　Google　Scholar　during　2010-2020　on　pharmacoeconomic　studies　related　to　overweight　and　obesity　in　China.　We　identified　five　cost-of-illness　studies　and　four　cost-effectiveness　analyses　of　weight-loss　interventions,　including　bariatric　surgeries　and　a　comprehensive　intervention　program.　Expert　opinion:　There　is　a　lack　of　pharmacoeconomic　analyses　of　obesity　in　China.　Existing　studies　have　often　taken　the　health　system　perspective　without　accounting　for　productivity　loss.　Cohort　studies　and　studies　based　on　electronic　health　records　or　claims　data　are　needed　to　provide　the　epidemiologic　parameters　required　for　homegrown　economic　evaluations　of　the　health　and　economic　burdens　of　obesity　in　China,　as　well　as　the　cost-effectiveness　of　interventions　to　reduce　obesity　and　its　sequela.